REPORT FROM THE 2009 AAN ANNUAL MEETING – Early progression of disability, a high relapse rate and ongoing MRI activity appear to be indicators of an inadequate response to disease-modifying therapy, according to the 15-year follow-up results of the MS Collaborative Study Group pivotal trial of beta-interferon-1a (Avonex) (Bermel et al. AAN 2009; abstract P02.117).
Read More
Neurology
Prospective trial of vitamin D in MS
July 21, 2009
Leave a reply
REPORT FROM THE 2009 AAN ANNUAL MEETING – High-dose vitamin D3 supplementation appears to be well tolerated and significantly reduces T cell reactivity, according to the results of a prospective Canadian trial (Burton et al. AAN 2009; abstract P01.110).
Read More
Preliminary results of rituximab in progressive MS
July 21, 2009REPORT FROM THE 2009 AAN ANNUAL MEETING – Two studies have investigated the potential benefits of rituximab, a monoclonal antibody that targets CD20 B cells, in primary- and secondary-progressive MS (PPMS, SPMS).
Read More
Donepezil slows decline in ADL
July 7, 2009REPORT FROM THE 2009 AAN ANNUAL MEETING – A pooled analysis (n=2,177) of six randomized double-blind trials of donepezil in Alzheimers disease has found that treatment is associated with a reduced decline in activities of daily living (ADL) (Gauthier et al. AAN 2009; abstract P06.079).
Read More
Risk of Parkinsons disease with cumulative lead exposure
July 7, 2009REPORT FROM THE 2009 AAN ANNUAL MEETING – A new multicentre study has found an increasing risk of Parkinsons disease with cumulative exposure to lead (Weisskopf et al. AAN 2009; abstract S23.001).
Read More